Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice.

[1]  P. Elliott,et al.  Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. , 2020, JACC. Heart failure.

[2]  F. Domínguez,et al.  Transthyretin amyloid cardiomyopathy. , 2020, Medicina clinica.

[3]  M. Maurer,et al.  Systemic Amyloidosis due to Monoclonal Immunoglobulins: Cardiac Involvement. , 2020, Hematology/oncology clinics of North America.

[4]  A. Petrie,et al.  Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage , 2020, ESC heart failure.

[5]  M. Maurer,et al.  Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis , 2020, JACC. CardioOncology.

[6]  G. Lin,et al.  The Challenges in Chemotherapy and Stem Cell Transplantation for Light-Chain Amyloidosis. , 2020, The Canadian journal of cardiology.

[7]  A. Masri,et al.  Hot hearts on bone scintigraphy are not all amyloidosis: hydroxychloroquine-induced restrictive cardiomyopathy , 2020, European heart journal.

[8]  J. A. López,et al.  Perfil clínico y evolución de la amiloidosis cardiaca en un centro español de referencia , 2020 .

[9]  D. Kuypers,et al.  Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients , 2020, Kidney international reports.

[10]  G. Pontone,et al.  Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. , 2019, JACC. Cardiovascular imaging.

[11]  C. Rapezzi,et al.  Assessment of patients with hereditary transthyretin amyloidosis – understanding the impact of management and disease progression , 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[12]  M. Maurer,et al.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[13]  Brian Lilleness,et al.  Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. , 2019, Blood.

[14]  D. Eisenberg,et al.  Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[15]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[16]  A. Petrie,et al.  A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.

[17]  S. Solomon,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[18]  S. Solomon,et al.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[19]  M. Leon,et al.  Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement , 2017, European heart journal.

[20]  P. Elliott,et al.  Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis , 2017, Circulation.

[21]  A. Dispenzieri,et al.  Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. , 2016, Journal of the American College of Cardiology.

[22]  P. García-Pavía,et al.  Analysis of diagnostic and therapeutic strategies in advanced cardiac light-chain amyloidosis. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[23]  G. Merlini,et al.  What is new in diagnosis and management of light chain amyloidosis? , 2016, Blood.

[24]  A. Hagège,et al.  Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. , 2016, European heart journal.

[25]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[26]  J. Maleszewski Cardiac amyloidosis: pathology, nomenclature, and typing. , 2015, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[27]  E. González-López,et al.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.

[28]  D. Dingli,et al.  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  G. Merlini,et al.  Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. , 2009, Clinical chemistry.